Homogeneous purification of human recombinant GST-Akt/PKB from Sf9 cells

Protein Expression and Purification

Volumn 17, Issue 1, 1999, Pages 83-88

  Fabbro, Doriano ^a   Batt, David ^b   Rose, Paul ^b   Schacher, Barbara ^a   Roberts, Thomas M ^b   Ferrari, Stefano ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME SYNTHESIS; HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLATION; POLYPHOSPHOINOSITIDE; RECOMBINANT PROTEIN; SIGNAL TRANSDUCTION;

EID: 0033213594     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.1999.1102     Document Type: Article

References (30)

1. Jacobson M. D., Weil M., Raff M. C. Programmed cell death in animal development. Cell. 88:1997;347-354.
2. Marte B. M., Downward J. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22:1997;355-358.
3. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-588.
4. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10:1998;262-267.
5. Burgering B. M., Coffer P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376:1995;599-602.
6. Staal S. P., Hartley J. W., Rowe W. P. Isolation of murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc. Natl. Acad. Sci. USA. 74:1977;3065-3067.
7. Bellacosa A., de Feo A., Godwin A. K., Bell D. W., Cheng J. Q., Altomare D. A., Wan M., Dubeau L., Scambia G, Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J. R. Molecular alteration of the Akt2 oncogene in ovarian and breast carcinomas. Int. J. Cancer. 64:1995;280-285.
8. Cheng J. Q., Ruggeri B., Klein W. M., Sonoda G., Altomare D. A., Watson D. K., Testa J. R. Amplification of Akt2 in human pancreatic cancer cells and inhibition of Akt2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA. 93:1996;3636-3641.
9. Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15:1996;6541-6551.
10. Frech M., Andjelkovic M., Ingley E., Reddy K. K., Falck J. R., Hemmings B. A. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin-homology domain of Rac/protein kinase B and their influence on the kinase activity. J. Biol. Chem. 272:1997;8474-8481.
11. Andjelkovic M., Jakubowicz T., Cron P., Ming X. F., Han J. W., Hemmings B. A. Activation and phosphorylation of pleckstrin-homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. USA. 93:1996;5699-5704.
12. Alessi D. R., James S. R., Downes C. P., Holmes A. B., Gaffney P., Reece P., Cohen P. Purification and characterisation of a phosphatidylinositol 3,4,5 trisphosphate-dependent protein kinase (PDK1) that phosphorylates and activates protein kinase Bα Curr. Biol. 7:1997;261-269.
13. Konishi H., Matsuzaki H., Tanaka M., Ono Y., Tokunaga C., Kuroda S., Kikkawa U. Activation of RAC-protein kinase by heat shock and hyperosmolarity stress through a pathway independent of phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA. 93:1996;7639-7643.
14. Cross D. A. E., Alessi D. R., Cohen P., Andjelkovic M., Hemmings B. A. Inhibition of glycogen synthase kinase-3 by insulin activated protein kinase B. Nature. 378:1995;785-789.
15. Welsh G. I. Glycogen synthase kinase-3. Trends Cell Biol. 6:1996;274-278.
16. Datta S. R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
17. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding of 14-3-3 not BCL-X. Cell. 87:1996;619-628.
18. Marte B. M., Rodriguez-Viciana P., Wennstrom S., Warne P. H., Downward J. PI3K and PKB/Akt act as an effector pathway for R-Ras. Curr. Biol. 7:1997;63-70.
19. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P. H., Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide-3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16:1997;2783-2793.
20. s6k produced as a function of the infectious response. J. Biol. Chem. 268:1993;7134-7138.
21. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
22. Ferrari S., Thomas G. Micro- and macropurification methods for protein kinases. Methods Enzymol. 200:1991;159-169.
23. Kozma S. C., Ferrari S., Bassand P., Siegmann M., Totty N., Thomas G. Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc. Natl. Acad. Sci. USA. 87:1990;7365-7369.
24. Alessi D. R., Caudwell F. B., Andjelkovic M., Hemmings B. A., Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399:1996;333-338.
25. Fabbro D., Buchdunger E., Wood J., Mestan J., Hofmann F., Ferrari S., Mett H., O'Reilly T., Meyer T. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82:1999;293-301.
26. Marte B. M., Meyer T., Stabel S., Jaken S., Fabbro D., Hynes N. E. Protein kinase C and mammary cell differentiation: An essential role for PKC-α in the induction of β-casein expression. Cell Growth Differ. 5:1994;239-247.
27. Geiges D., Meyer T., Marte B., Vanek M., Weissgerber G., Stabel S., Pfeilschifter J., Fabbro D., Huwiler A. Activation of PKC subtypes α, γ, δ, ε, ζ and η by tumor promoting and non-tumor promoting agents. Biochem. Pharmacol. 53:1997;865-875.
28. Traxler P. Tyrosine kinase inhibitors in cancer treatment (Part II). Exp. Opin. Ther. Patents. 8:1998;1509-1622.
29. Furet P., Cravatti G., Lydon N., Priestlke J. P., Sowadski J. M., Trinks U., Traxler P. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of selectivity of CGP 52411. J. Comput. Aided Mol. Dis. 9:1995;465-472.
30. Fersht A. Enzyme Structure and Mechanism. 1985;Freeman, Oxford. p. 106-107.